Novo Nordisk: Next-Generation GLP-1/Amylin Drug Sees Leading Weight Loss in Small Trial
Novo Nordisk’s NVO amycretin, which targets GLP-1 and amylin in one molecule, generated 24% placebo-adjusted weight loss in a ...
Novo Nordisk next-gen shot shows 22% weight loss in early results
One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...
Novo Nordisk Stock Jumps on Early Stage Weight-Loss Drug Trial Results
Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for ...
Ozempic maker’s stock surges. A trial of a new Novo Nordisk drug shows promise.
Novo Nordisk shares jumped on Friday as the Danish drugmaker said an experimental drug was able to reduce weight by as much ...
STAT6h
Novo Nordisk’s next-generation obesity treatment shows promise in early study
A new weight loss drug from Novo Nordisk helped patients lose a large amount of weight, providing a boost for Novo in the ...
Novo Rises After Experimental Shot Delivers 22% Weight Loss
Novo Nordisk A/S rose the most in a month after an experimental shot delivered as much as 22% weight loss in an early-stage ...
ncbiotech.org15h
Azzur serves NC biosciences with “Cleanrooms on Demand”
Azzur Cleanrooms on Demand (COD) has entered this acronym-laden environment to provide cleanroom and laboratory spaces for so-called GxP manufacturing support. Opened in May 2023, it’s a 75,000-square ...